KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) has been assigned a consensus broker rating score of 0.00 () from the zero analysts that provide coverage for the stock, Zacks Investment Research reports.

Zacks has also given KaloBios Pharmaceuticals an industry rank of 167 out of 265 based on the ratings given to related companies.

COPYRIGHT VIOLATION NOTICE: “KaloBios Pharmaceuticals Inc (KBIO) Receives Consensus Recommendation of “” from Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/20/kalobios-pharmaceuticals-inc-kbio-receives-consensus-recommendation-of-from-analysts.html.

KaloBios Pharmaceuticals (NASDAQ:KBIO) opened at 1.6739 on Thursday. KaloBios Pharmaceuticals has a 52 week low of $1.50 and a 52 week high of $4.75. The stock has a 50 day moving average of $2.01 and a 200 day moving average of $2.61. The company’s market cap is $25.07 million.

KaloBios Pharmaceuticals Company Profile

KaloBios Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.

Get a free copy of the Zacks research report on KaloBios Pharmaceuticals (KBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KaloBios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KaloBios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.